Blog
Daily evidence-led peptide research, regulatory news, expert digest and explainers. Every claim sourced; no AI tells.
Page 67
The obesity drug pipeline in 2026
A 2026 JCEM review maps next-generation obesity drugs, from approved dual agonists to triple agonists like retatrutide still in Phase 3.
Semaglutide for MASH: the corrected review
Liver International published an erratum in August 2026 to the Petta et al. semaglutide MASH review. Here is what the original said and what a correction means.
Semaglutide optic neuropathy: correction
JCEM Case Reports issued a formal correction in July 2026 to a May 2026 case report on optic nerve injury after semaglutide escalation.
Tirzepatide: PERCEPTIONS survey findings
The PERCEPTIONS survey (n=518, US) found health improvement was the top reason patients started tirzepatide; cost and insurance were the main barriers.
Mounjaro on X: who shapes the conversation
A 2026 study of 5,566 Mounjaro tweets found that the top influencers on X are patients and public figures, not clinicians.
Semaglutide alters NAc oscillations in mice
Molecular Brain (July 2026) finds semaglutide changes nucleus accumbens oscillations and reward behaviour in healthy mice, not just in metabolic disease models.
TAAR1: the metabolic target after GLP-1
A 2026 pharmacology review argues TAAR1 can replicate GLP-1 agonist effects through a distinct receptor, with additional action on brain reward circuits.
TB-500 cost in the Netherlands
TB-500 has no EU marketing authorisation and no Dutch insurance coverage. No verified pharmacy price exists in the Netherlands.
TB-500 in the Netherlands: legal status
TB-500 has no marketing authorisation in the Netherlands. This page explains how the Geneesmiddelenwet, the CBG-MEB register, and the WADA sport ban apply.
Tesamorelin Netherlands: import rules
Tesamorelin has no EU marketing authorisation. The Netherlands has no registered product. What Dutch law, CBG-MEB rules, and customs mean for personal import.
Tesamorelin Netherlands: regulatory status
Tesamorelin has no EU marketing authorisation. The EMA application was withdrawn in 2012. Here is what Dutch patients and clinicians need to know.
Tirzepatide in Netherlands: Mounjaro access
Mounjaro (tirzepatide) has held an EMA marketing authorisation in the Netherlands since 2022. Here is what the licence covers and how Dutch reimbursement works.